Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-2216

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-2216). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2216 3)

The label for Losartan Potassium 100 mg film-coated tablets by NuCare Pharmaceuticals, Inc. It specifies a package of 30 tablets, with each tear drop-shaped, white/off-white tablet debossed with 'H' on one side and '145' on the other. Rx only, with storage instructions at 68-77°F and a warning to keep out of reach of children. Manufacturer is Hetero Labs Limited, India.*

FDA Label Image

Pdp (Camber)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over 60 study months between atenolol (dotted line) and losartan potassium (solid line). The graph includes a note indicating an Adjusted Risk Reduction of 13% with a p-value of 0.021, showing a trend over time.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of 66 months between two treatments: Atenolol and Losartan Potassium. The graph shows adjusted risk reduction data indicating 25% with statistical significance at p=0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot titled 'Figure 3: Primary Endpoint Events within Demographic Subgroups' comparing event rates and hazard ratios for Losartan Potassium versus Atenolol. It shows data for overall patients and subgroups by age, gender, race, ISH, diabetes, and history of cardiovascular disease. The plot presents hazard ratios with 95% confidence intervals for primary composite events and stroke (fatal/non-fatal). Sample size and percentage event rates per group are included.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The Y-axis shows percentage of patients with events, and the X-axis shows months. The graph indicates a risk reduction statistic with a p-value, illustrating the difference in outcomes between the two groups.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of Losartan Potassium showing its molecular components including substituted rings and potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.